GLP-1 Therapies Newsletter
Issue #40June 8, 20267 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

GLP-1 drugs like Ozempic and Wegovy are transforming weight loss, but this week's research reveals some unexpected complications—and promising new applications beyond diabetes and obesity.

🚨 GLP-1 Users Face Higher Aspiration Risk During Emergency Stroke Surgery

  • 740 stroke patients undergoing emergency clot removal surgery were tracked, with 41 (5.5%) actively using GLP-1 drugs like semaglutide
  • GLP-1 users had aspiration pneumonia in 26.8% of cases versus 10.3% in non-users—a 16.5 percentage point increase in absolute risk
  • The increased aspiration risk didn't affect stroke outcomes or brain bleeding rates, but highlights a serious procedural complication

Why it matters: GLP-1 drugs slow stomach emptying, which can leave food in the stomach longer and increase aspiration risk during emergency procedures. This suggests stroke teams may need targeted prevention strategies for GLP-1 users without delaying life-saving treatment.

🎖️ Top 10% journal 🔗 Journal of neurointerventional surgery Journal Article 🗓️ Jun 5

Key Findings

💊 New Oral GLP-1 Drug Delivers Injectable-Level Weight Loss

  • 230 adults with obesity tested oral semaglutide (Wegovy pills) against placebo for 36 weeks
  • Weight loss reached 8.2%, 9.8%, and 11.3% with increasing doses (45mg, 90mg, 120mg) versus placebo
  • Only 10.4% stopped treatment due to side effects, with no liver injury cases reported
💡 Oral GLP-1 drugs may offer similar benefits to injections while being more convenient for patients who prefer pills.
🔗 Nature medicine Journal Article 🗓️ Jun 5

🔬 Mice Study Shows How to Prevent GLP-1 Muscle Loss

  • Mice on semaglutide lost significant muscle mass but maintained muscle strength during weight loss
  • Adding a drug that blocks 15-PGDH (a muscle-degrading enzyme) preserved muscle growth and enhanced strength recovery after injury
  • The combination maintained weight loss benefits while protecting muscle tissue
💡 This mouse study suggests potential strategies to preserve muscle mass during GLP-1-induced weight loss.
🔗 Proc Natl Acad Sci U S A Journal Article 🗓️ Jun 2

🎯 GLP-1 Users Show 35% Lower Breast Cancer Risk

  • 111,646 women aged 45-80 undergoing breast imaging were tracked, with GLP-1 exposure linked to 35% lower breast cancer incidence
  • The protective association remained after accounting for age, race, BMI, breast density, and diabetes status
  • The effect appeared independent of weight loss alone, suggesting GLP-1 drugs may have direct anti-cancer properties
💡 GLP-1 drugs may offer unexpected cancer protection benefits beyond their metabolic effects.
🥉 Top 5% journal 🔗 JCO oncology practice Journal Article 🗓️ Jun 2

⚠️ Patients Report Major Eating Disorder Concerns

  • 30 adolescents and young adults (ages 12-22) shared experiences with GLP-1 weight loss medications through detailed interviews
  • Many reported reduced appetite and 'food noise,' but families expressed uncertainty about when to stop treatment
  • Stigma about medication use was common, with variable quality of medical support and education
💡 Young GLP-1 users need better screening for eating disorders and clearer guidance on long-term treatment decisions.
🎖️ Top 10% journal 🔗 J Adolesc Health Journal Article 🗓️ Jun 3

🏥 Post-Surgery Weight Regain Responds Well to GLP-1s

  • 111 patients who had sleeve gastrectomy over 10 years ago were tracked, with 44 using GLP-1 drugs for weight regain
  • GLP-1 users achieved 25.7% total weight loss versus 14.1% in non-users at 10+ years post-surgery
  • Patients typically started GLP-1s about 7.6 years after surgery and had been using them for 3 years on average
💡 GLP-1 drugs may help optimize long-term weight outcomes even years after bariatric surgery.
🎖️ Top 10% journal 🔗 International journal of obesity (2005) Journal Article 🗓️ Jun 1

🧠 Brain Study Reveals How GLP-1s Affect Addiction Circuits

  • Mouse brain tissue analysis showed GLP-1 and GIP receptors are present in the lateral septum, a key reward processing area
  • Both receptor types reduced dopamine release and cocaine's ability to increase brain dopamine levels
  • The receptors often appeared together in the same brain cells, suggesting coordinated effects on addiction pathways
💡 This mouse study may explain why GLP-1 drugs appear to reduce cravings for alcohol, nicotine, and other substances.
Top 20% journal 🔗 ACS chemical neuroscience Journal Article 🗓️ Jun 1

Implications

This week's research shows GLP-1 drugs are revealing both new risks and unexpected benefits. While procedural complications like aspiration require clinical attention, the emerging evidence for cancer protection and addiction treatment suggests these medications may have far broader therapeutic potential than originally recognized.

Studies in this issue

Primary sources used for this newsletter.

  1. Use of GLP-1 receptor drugs and risk of breathing-related lung infection after blood clot removal treatment
    main storyJournal of neurointerventional surgery2026-06-05PMID 42248677
  2. Glucose-Dependent Insulinotropic Polypeptide Receptors in the Emotion System Reduce Dopamine Release and Cocaine's Effect on Dopamine
    key findingACS chemical neuroscience2026-06-01PMID 42219687
  3. Effects of the oral drug aleniglipron on people with overweight or obesity in a controlled clinical trial
    key findingNature medicine2026-06-05PMID 42249138
  4. Young People’s Experiences Using Weight Loss Medications: Choices, Eating Habits, and Uncertainty About How Long to Take Them
    key findingThe Journal of adolescent health : official publication of the Society for Adolescent Medicine2026-06-03PMID 42233931
  5. GLP-1 Drugs Are Linked to Lower Breast Cancer Rates in Women
    key findingJCO oncology practice2026-06-02PMID 42227662
  6. How additional weight-loss medicines affect 10-year results after sleeve gastrectomy
    key findingInternational journal of obesity (2005)2026-06-01PMID 42225949
  7. Blocking 15-PGDH helps muscle repair and strength recovery during weight loss caused by GLP-1 receptor drugs
    key findingProceedings of the National Academy of Sciences of the United States of America2026-06-02PMID 42228536

Continue reading

All GLP-1 Therapies issues